SUZHOU BASECARE MEDICAL CORPORATION LIMITED Suzhou Basecare Medical Corporation Limited Share Price
Equities
2170
CNE100004BC1
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.01 HKD | +0.50% |
|
+0.50% | -14.47% |
| Sales 2023 | 208M 28.7M 225M 2.39B | Sales 2024 * | 459M 63.28M 495M 5.28B | Capitalization | 495M 68.28M 534M 5.69B |
|---|---|---|---|---|---|
| Net income 2023 | -192M -26.5M -207M -2.21B | Net income 2024 * | -78M -10.76M -84.26M -898M | EV / Sales 2023 | 2.73 x |
| Net cash position 2023 * | - 0 0 0 | Net cash position 2024 * | - 0 0 0 | EV / Sales 2024 * | 1.08 x |
| P/E ratio 2023 |
-3.05
x | P/E ratio 2024 * |
-6.32
x | Employees | 586 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 26.54% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.50% | ||
| 1 week | +0.50% | ||
| 1 month | -0.50% | ||
| 3 months | -6.51% | ||
| 6 months | -25.56% | ||
| Current year | -14.47% |
1 week
1.90
2.05
1 month
1.832.22
Current year
1.832.40
1 year
1.834.81
3 years
1.8328.90
5 years
1.8334.85
10 years
1.8334.85
| Managers | Title | Age | Since |
|---|---|---|---|
Bo Liang
CEO | Chief Executive Officer | 44 | 14/10/14 |
Le Jun Yin
DFI | Director of Finance/CFO | 39 | 28/22/28 |
Mao She Rui
COO | Chief Operating Officer | 36 | 17/14/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xi Xiong Kang
BRD | Director/Board Member | 72 | 16/21/16 |
Bo Liang
CEO | Chief Executive Officer | 44 | 14/10/14 |
Mao She Rui
COO | Chief Operating Officer | 36 | 17/14/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2.01 | +0.50% | 31,500 |
| 25/24/25 | 2 | -1.48% | 13,200 |
| 24/24/24 | 2.03 | +1.50% | 6,000 |
| 23/24/23 | 2 | +2.56% | 30,500 |
| 22/24/22 | 1.95 | -2.50% | 3,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST
More quotes
Suzhou Basecare Medical Co Ltd, formerly Jiangsu Double Helix Biology Science and Technology Co Ltd, is a China-based investment holding company mainly engaged in the provision of assisted reproductive genetic testing solutions. The Company provides genetic testing solutions and sells genetic testing equipment and instruments. The genetic testing solutions include sales of testing kits and provision of testing services. The Company's main products include PGT-A kits. The Company mainly conducts business within the domestic market.
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.861
CNY
Average target price
11.18
CNY
Spread / Average Target
+501.04%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.47% | 68.27M | |
| -17.89% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- 2170 Stock
